Sandoz Completes Acquisition of Generic Dermatology Company Fougera for $1.5 Billion - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Sandoz Completes Acquisition of Generic Dermatology Company Fougera for $1.5 Billion


ePT--the Electronic Newsletter of Pharmaceutical Technology

Sandoz Completes Acquisition of Generic Dermatology Company Fougera for $1.5 Billion

Sandoz announced it has completed the acquisition of Fougera Pharmaceuticals, a maker of generic dermatology products, for $1.525 billion in an all-cash transaction. According to a company press release, the acquisition will complement Sandoz’s existing pipeline of biosimilars and generic injectables, ophthalmics, and antibiotics. Sandoz plans to use its global reach to expand Fougera’s dermatology portfolio into new markets.

Currently, Fougera Pharmaceuticals employs approximately 700 people across its US sites. It operates two main businesses: Fougera, specializing in dermatology development and manufacturing, with expertise in the area of semi-solid forms such as creams and ointments, and PharmaDerm, a branded specialty pharma business.

Fougera will be integrated into Sandoz’s US business based in Princeton, New Jersey, but will continue to exist as a separate legal entity. Fougera’s site in Melville, New York, will be home to a new center of excellence for generic dermatology development and manufacturing within the global Sandoz network.

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
26%
Oversee medical treatment of patients in the US.
13%
Provide treatment for patients globally.
11%
All of the above.
39%
No government involvement in patient treatment or drug development.
11%
Jim Miller Outsourcing Outlook Jim MillerCMO Industry Thins Out
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerFluorination Remains Key Challenge in API Synthesis
Marilyn E. Morris Guest EditorialMarilyn E. MorrisBolstering Graduate Education and Research Programs
Jill Wechsler Regulatory Watch Jill Wechsler Biopharma Manufacturers Respond to Ebola Crisis
Sean Milmo European Regulatory WatchSean MilmoHarmonizing Marketing Approval of Generic Drugs in Europe
FDA Reorganization to Promote Drug Quality
FDA Readies Quality Metrics Measures
New FDA Team to Spur Modern Drug Manufacturing
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Source: ePT--the Electronic Newsletter of Pharmaceutical Technology,
Click here